{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:57:11Z","timestamp":1791266231434,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T00:00:00Z","timestamp":1398297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/bjc.2014.220","type":"journal-article","created":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T23:03:06Z","timestamp":1398380586000},"page":"2479-2488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma"],"prefix":"10.1038","volume":"110","author":[{"given":"S","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Eilers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Corson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W-B","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,24]]},"reference":[{"key":"BFbjc2014220_CR1","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De RA, Jhanwar SC, Mossman BT, Kane AB, Testa JR (2005) Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24: 6080\u20136089.","journal-title":"Oncogene"},{"key":"BFbjc2014220_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","volume":"6","author":"M Brevet","year":"2011","unstructured":"Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, Rusch V, Ladanyi M (2011) Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol 6: 864\u2013874.","journal-title":"J Thorac Oncol"},{"key":"BFbjc2014220_CR3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","volume":"18","author":"M Carbone","year":"2012","unstructured":"Carbone M, Yang H (2012) Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 18: 598\u2013604.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014220_CR4","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065\u20133074.","journal-title":"J Clin Invest"},{"key":"BFbjc2014220_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","volume":"77","author":"S Cedres","year":"2012","unstructured":"Cedres S, Montero MA, Martinez P, Martinez A, Rodriguez-Freixinos V, Torrejon D, Gabaldon A, Salcedo M, Ramon YC, Felip E (2012) Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 77: 192\u2013198.","journal-title":"Lung Cancer"},{"key":"BFbjc2014220_CR6","doi-asserted-by":"publisher","first-page":"7684","DOI":"10.1158\/0008-5472.CAN-09-3231","volume":"70","author":"X Cheng","year":"2010","unstructured":"Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC (2010) Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Res 70: 7684\u20137689.","journal-title":"Cancer Res"},{"key":"BFbjc2014220_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0046-8177(87)80354-4","volume":"18","author":"JE Craighead","year":"1987","unstructured":"Craighead JE (1987) Current pathogenetic concepts of diffuse malignant mesothelioma. Hum Pathol 18: 544\u2013557.","journal-title":"Hum Pathol"},{"key":"BFbjc2014220_CR8","first-page":"809","volume":"26","author":"GW Cole Jr","year":"2006","unstructured":"Cole GW Jr, Alleva AM, Zuo JT, Sehgal SS, Yeow WS, Schrump DS, Nguyen DM (2006) Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res 26: 809\u2013821.","journal-title":"Anticancer Res"},{"key":"BFbjc2014220_CR9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood.V74.3.940.940","volume":"74","author":"GD Demetri","year":"1989","unstructured":"Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD (1989) Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood 74: 940\u2013946.","journal-title":"Blood"},{"key":"BFbjc2014220_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2012.07.005","volume":"78","author":"B Fischer","year":"2012","unstructured":"Fischer B, Frei C, Moura U, Stahel R, Felley-Bosco E (2012) Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer 78: 23\u201329.","journal-title":"Lung Cancer"},{"key":"BFbjc2014220_CR11","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","volume":"166","author":"GJ Gordon","year":"2005","unstructured":"Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, Bueno R (2005) Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166: 1827\u20131840.","journal-title":"Am J Pathol"},{"key":"BFbjc2014220_CR12","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","volume":"11","author":"R Govindan","year":"2005","unstructured":"Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL (2005) Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11: 2300\u20132304.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014220_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1054\/bjoc.2000.1445","volume":"83","author":"P Harvey","year":"2000","unstructured":"Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR (2000) Hepatocyte growth factor\/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83: 1147\u20131153.","journal-title":"Br J Cancer"},{"key":"BFbjc2014220_CR14","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1158\/1078-0432.CCR-12-2716","volume":"19","author":"A Herzog","year":"2013","unstructured":"Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C (2013) PI3K\/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 19: 3808\u20133819.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014220_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/sj.bjc.6605184","volume":"101","author":"BA Jacobson","year":"2009","unstructured":"Jacobson BA, De A, Kratzke MG, Patel MR, Jay-Dixon J, Whitson BA, Sadiq AA, Bitterman PB, Polunovsky VA, Kratzke RA (2009) Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. Br J Cancer 101: 424\u2013431.","journal-title":"Br J Cancer"},{"key":"BFbjc2014220_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","volume":"66","author":"R Jagadeeswaran","year":"2006","unstructured":"Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R (2006) Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352\u2013361.","journal-title":"Cancer Res"},{"key":"BFbjc2014220_CR17","first-page":"5242","volume":"62","author":"PA Janne","year":"2002","unstructured":"Janne PA, Taffaro ML, Salgia R, Johnson BE (2002) Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62: 5242\u20135247.","journal-title":"Cancer Res"},{"key":"BFbjc2014220_CR18","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","volume":"30","author":"K Kawaguchi","year":"2009","unstructured":"Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y (2009) Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 30: 1097\u20131105.","journal-title":"Carcinogenesis"},{"key":"BFbjc2014220_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G","volume":"76","author":"J Klominek","year":"1998","unstructured":"Klominek J, Baskin B, Liu Z, Hauzenberger D (1998) Hepatocyte growth factor\/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 76: 240\u2013249.","journal-title":"Int J Cancer"},{"key":"BFbjc2014220_CR20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm1052","volume":"10","author":"PK Majumder","year":"2004","unstructured":"Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594\u2013601.","journal-title":"Nat Med"},{"key":"BFbjc2014220_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","volume":"50","author":"A Mathy","year":"2005","unstructured":"Mathy A, Baas P, Dalesio O, van ZN (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50: 83\u201386.","journal-title":"Lung Cancer"},{"key":"BFbjc2014220_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1947601910375273","volume":"1","author":"CW Menges","year":"2010","unstructured":"Menges CW, Chen Y, Mossman BT, Chernoff J, Yeung AT, Testa JR (2010) A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 1: 493\u2013505.","journal-title":"Genes Cancer"},{"key":"BFbjc2014220_CR23","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1158\/1541-7786.MCR-12-0082","volume":"10","author":"CW Menges","year":"2012","unstructured":"Menges CW, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson JR, Testa JR (2012) Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res 10: 1178\u20131188.","journal-title":"Mol Cancer Res"},{"key":"BFbjc2014220_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3892\/ijo.2012.1462","volume":"41","author":"S Miyoshi","year":"2012","unstructured":"Miyoshi S, Hamada H, Hamaguchi N, Kato A, Katayama H, Irifune K, Ito R, Miyazaki T, Okura T, Higaki J (2012) Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo. Int J Oncol 41: 449\u2013456.","journal-title":"Int J Oncol"},{"key":"BFbjc2014220_CR25","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1158\/1078-0432.CCR-05-1191","volume":"11","author":"T Mukohara","year":"2005","unstructured":"Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Janne PA (2005) Inhibition of the met receptor in mesothelioma. Clin Cancer Res 11: 8122\u20138130.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014220_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/JTO.0b013e3181839693","volume":"3","author":"J Okamoto","year":"2008","unstructured":"Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He B, Jablons DM (2008) Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 3: 1089\u20131095.","journal-title":"J Thorac Oncol"},{"key":"BFbjc2014220_CR27","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/onc.2010.555","volume":"30","author":"WB Ou","year":"2011","unstructured":"Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA (2011a) AXL regulates mesothelioma proliferation and invasiveness. Oncogene 30: 1643\u20131652.","journal-title":"Oncogene"},{"key":"BFbjc2014220_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1593\/neo.101156","volume":"13","author":"WB Ou","year":"2011","unstructured":"Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA (2011b) Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 13: 12\u201322.","journal-title":"Neoplasia"},{"key":"BFbjc2014220_CR29","first-page":"333","volume":"152","author":"JC Pache","year":"1998","unstructured":"Pache JC, Janssen YM, Walsh ES, Quinlan TR, Zanella CL, Low RB, Taatjes DJ, Mossman BT (1998) Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol 152: 333\u2013340.","journal-title":"Am J Pathol"},{"key":"BFbjc2014220_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/JTO.0b013e31811f3aab","volume":"2","author":"MR Patel","year":"2007","unstructured":"Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA (2007) Ras pathway activation in malignant mesothelioma. J Thorac Oncol 2: 789\u2013795.","journal-title":"J Thorac Oncol"},{"key":"BFbjc2014220_CR31","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1016\/j.ejca.2010.06.130","volume":"46","author":"F Perrone","year":"2010","unstructured":"Perrone F, Jocolle G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De MC, Bertan C, Cabras A, Bertulli R, Pierotti MA, Zaffaroni N, Pilotti S (2010) Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer 46: 2837\u20132848.","journal-title":"Eur J Cancer"},{"key":"BFbjc2014220_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/bjc.2013.9","volume":"108","author":"DJ Pinato","year":"2013","unstructured":"Pinato DJ, Mauri FA, Lloyd T, Vaira V, Casadio C, Boldorini RL, Sharma R (2013) The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br J Cancer 108: 621\u2013628.","journal-title":"Br J Cancer"},{"key":"BFbjc2014220_CR33","doi-asserted-by":"publisher","first-page":"e36856","DOI":"10.1371\/journal.pone.0036856","volume":"7","author":"G Pinton","year":"2012","unstructured":"Pinton G, Manente AG, Angeli G, Mutti L, Moro L (2012) Perifosine as a potential novel anti-cancer agent inhibits EGFR\/MET-AKT axis in malignant pleural mesothelioma. PLoS One 7: e36856.","journal-title":"PLoS One"},{"key":"BFbjc2014220_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","volume":"1","author":"VS Rodrik-Outmezguine","year":"2011","unstructured":"Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1: 248\u2013259.","journal-title":"Cancer Discov"},{"key":"BFbjc2014220_CR35","first-page":"8118","volume":"61","author":"BP Rubin","year":"2001","unstructured":"Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118\u20138121.","journal-title":"Cancer Res"},{"key":"BFbjc2014220_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2214\/ajr.161.3.8394641","volume":"161","author":"AA Sahin","year":"1993","unstructured":"Sahin AA, Coplu L, Selcuk ZT, Eryilmaz M, Emri S, Akhan O, Baris YI (1993) Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients. AJR Am J Roentgenol 161: 533\u2013537.","journal-title":"AJR Am J Roentgenol"},{"key":"BFbjc2014220_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1378\/chest.102.3.790","volume":"102","author":"ZT Selcuk","year":"1992","unstructured":"Selcuk ZT, Coplu L, Emri S, Kalyoncu AF, Sahin AA, Baris YI (1992) Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest 102: 790\u2013796.","journal-title":"Chest"},{"key":"BFbjc2014220_CR38","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/ijc.25763","volume":"129","author":"A Shukla","year":"2011","unstructured":"Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT (2011) ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer 129: 1075\u20131086.","journal-title":"Int J Cancer"},{"key":"BFbjc2014220_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/cdd.2012.153","volume":"20","author":"S Singh","year":"2013","unstructured":"Singh S, Ramamoorthy M, Vaughan C, Yeudall WA, Deb S, Palit DS (2013) Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death Differ 20: 558\u2013566.","journal-title":"Cell Death Differ"},{"key":"BFbjc2014220_CR40","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening.J. Natl Cancer Inst 82: 1107\u20131112.","journal-title":"Natl Cancer Inst"},{"key":"BFbjc2014220_CR41","first-page":"181","volume":"2","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Report 2: 181\u2013188.","journal-title":"Mol Med Report"},{"key":"BFbjc2014220_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s004320050171","volume":"124","author":"E Tolnay","year":"1998","unstructured":"Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM (1998) Hepatocyte growth factor\/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124: 291\u2013296.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFbjc2014220_CR43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.25555","volume":"117","author":"S Varghese","year":"2011","unstructured":"Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR Jr. (2011) Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 117: 361\u2013371.","journal-title":"Cancer"},{"key":"BFbjc2014220_CR44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel HG, de SE, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332\u2013337.","journal-title":"Nature"},{"key":"BFbjc2014220_CR45","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/1078-0432.CCR-04-2109","volume":"11","author":"G Xia","year":"2005","unstructured":"Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS (2005) Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res 11: 4305\u20134315.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014220_CR46","first-page":"5334","volume":"56","author":"CL Zanella","year":"1996","unstructured":"Zanella CL, Posada J, Tritton TR, Mossman BT (1996) Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 56: 5334\u20135338.","journal-title":"Cancer Res"},{"key":"BFbjc2014220_CR47","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1101-973","volume":"3","author":"BP Zhou","year":"2001","unstructured":"Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC (2001) HER-2\/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973\u2013982.","journal-title":"Nat Cell Biol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014220","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:23:04Z","timestamp":1684416184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,24]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFbjc2014220"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.220","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,24]]},"assertion":[{"value":"16 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}